A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

BACKGROUND: Currently, there are no direct comparisons of apixaban and rivaroxaban, two new oral direct factor Xa inhibitors approved for management of thromboembolic disorders. OBJECTIVE: Compare the pharmacokinetics and anti-factor Xa activity (AXA) of apixaban and rivaroxaban. METHODS: In this ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Frost, Charles, Song, Yan, Barrett, Yu Chen, Wang, Jessie, Pursley, Janice, Boyd, Rebecca A, LaCreta, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235474/
https://www.ncbi.nlm.nih.gov/pubmed/25419161
http://dx.doi.org/10.2147/CPAA.S61131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235474/
https://www.ncbi.nlm.nih.gov/pubmed/25419161
http://dx.doi.org/10.2147/CPAA.S61131

Ejemplares similares